ArticleIranian journal of pathology2026
EGFR Gene Mutations in Tongue Squamous Cell Carcinoma: Frequency and Association with Clinicopathological Features.
Article in Iranian journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objective: Oral squamous cell carcinoma (OSCC) is the most common malignancy of the oral cavity. Epidermal growth factor receptor (EGFR) mutations are well recognized in lung cancer and several other epithelial tumors, but their role in tongue squamous cell carcinoma (TSCC) remains unclear. Understanding their frequency and clinical relevance may provide insight into their potential therapeutic significance. Methods: In this study, 30 paraffin-embedded tissue samples from patients with TSCC were examined. Demographic and clinicopathological data, including age, sex, tumor stage, histological grade, and recurrence, were collected. DNA was extracted, and mutations in exons 18 to 21 of the EGFR gene were analyzed using real-time polymerase chain reaction. Statistical analyses were performed to assess possible associations between EGFR mutation status and clinical or pathological features, as well as patient survival. Results: The mean age of the patients was 58.77 years, with an equal male-to-female distribution. EGFR mutation was identified in only one patient (3.3%), consisting of a deletion in exon 19. No significant associations were observed between EGFR mutation status and age, sex, tumor stage, histological grade, or recurrence. Survival analysis also showed no prognostic impact of EGFR mutation in this cohort. Conclusion: EGFR mutation appears to be rare in TSCC and was not significantly associated with clinicopathological features or patient survival in this study. Larger studies are needed to confirm these findings and to clarify any potential therapeutic implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.